Acorda Therapeutics Announces Promotions for Two Senior Management Team Members.Business Editors/Health/Medical Writers BIOWIRE2K HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb. 18, 2004 Acorda Therapeutics announced today the promotions of two members of its senior management team. Andrew R. Blight, Ph.D., previously the Company's Executive Vice President of Research and Development, has been promoted to Chief Scientific Officer. Dr. Blight is responsible for setting the strategic direction of all R&D programs and technology assessments within Acorda as well as providing scientific support to the Company's other departments, including clinical development, intellectual property, and marketing. Mary Fisher has been promoted from Vice President of Commercial Operations to Executive Vice President of Operations. In her new role, Ms. Fisher will retain primary responsibility for Acorda's Marketing, Sales, Communications and Strategic Planning, and will also assume responsibility for Commercial Manufacturing. Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. (SCI (Scalable Coherent Interface) An IEEE standard for a high-speed bus that uses wire or fiber-optic cable. It can transfer data up to 1GBytes/sec. (hardware) SCI - 1. Scalable Coherent Interface. 2. UART. ), multiple sclerosis (MS) and related central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials phase 3 clinical trial Phase 3 study. See Phase study. for chronic SCI and Phase 2 for MS. Acorda's technology platform also includes valrocemide, which is in clinical development for the treatment of epilepsy and bipolar disorder bipolar disorder, formerly manic-depressive disorder or manic-depression, severe mental disorder involving manic episodes that are usually accompanied by episodes of depression. . Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord spinal cord, the part of the nervous system occupying the hollow interior (vertebral canal) of the series of vertebrae that form the spinal column, technically known as the vertebral column. and brain. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion